DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
46 hedge funds and large institutions have $7.38M invested in DMK Pharmaceuticals Corporation Common Stock in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 13 reducing their positions, and 7 closing their positions.
2,704% more call options, than puts
Call options by funds: $673K | Put options by funds: $24K
6% less funds holding
Funds holding: 49 → 46 (-3)
14% less capital invested
Capital invested by funds: $8.58M → $7.38M (-$1.2M)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
54% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$69.2K |
| 2 |
CCG
Capital CS Group
Irvine,
California
|
+$43.2K |
| 3 |
Creative Planning
Overland Park,
Kansas
|
+$38.6K |
| 4 |
State Street
Boston,
Massachusetts
|
+$33.8K |
| 5 |
BlackRock
New York
|
+$16.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$229K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$187K |
| 3 |
VF
Virtu Financial
New York
|
-$136K |
| 4 |
Millennium Management
New York
|
-$84K |
| 5 |
JP Morgan Chase
New York
|
-$82K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citigroup
New York
| – | +$172 | +4 | New |
|
DMK Hedge Fund Activity: Q1 2022 in Review
46 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q1 2022, worth a combined $7.38M — down 14% from $8.58M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of DMK and 4 opened new positions — a net loss of 3 holders — while 13 trimmed existing stakes and 6 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $69.2K. The largest seller was Citadel Advisors, cutting an estimated $229K.
- 46 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q1 2022, down from 49 in Q4 2021.
- Funds reported $7.38M of DMK Pharmaceuticals Corporation Common Stock stock for Q1 2022, down 14% quarter-over-quarter.
- 4 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q1 2022 and 7 closed out, a net change of -3 holders.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q1 2022 was Tower Research Capital (TRC), an estimated $69.2K added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q1 2022 was Citadel Advisors, an estimated $229K sold.
Based on aggregated 13F filings for Q1 2022.